NRXP · NRX Pharmaceuticals, Inc. · Analyst Estimates
$2.54
-0.01 (-0.39%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Nov 16, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As such, the Company has concluded that substantial doubt exists regarding the Company's ability to continue as a going concern for a period of at least *twelve* months from the date of issuance of these consolidated financial statements.”View the 10-Q filed Nov 16, 2026
Market Cap
$113.04M
Shares
44.33M
Volume · Nov 19
1.4M
Avg daily vol (3M)
1.06M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Analyst Estimates
Compare analyst forecasts for NRX Pharmaceuticals, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Pull consensus estimates through the analyst estimates API or MCP →Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-11-19 16:09 UTC · Publication dates shown per estimate · 8 metric / period groups
FY ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.80
|
-0.80
|
-0.80
|
1
|
-0.80
|
-0.80
|
-0.36
|
-0.36
|
1
|
1
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
4.49M
|
4.49M
|
4.49M
|
1
|
— | — | — | — | — | — | — | — |
FY ending 2027-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.35
|
-0.35
|
-0.35
|
1
|
-0.35
|
-0.35
|
0.50
|
0.50
|
1
|
1
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
6.00M
|
77.49M
|
228.50M
|
4
|
— | — | — | — | — | — | — | — |
Q ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.17
|
-0.17
|
-0.17
|
1
|
-0.17
|
-0.17
|
-0.03
|
-0.03
|
1
|
1
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
1.16M
|
1.16M
|
1.16M
|
1
|
— | — | — | — | — | — | — | — |
Q ending 2027-03-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.17
|
-0.17
|
-0.17
|
1
|
-0.17
|
-0.17
|
0.00
|
0.00
|
1
|
1
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
1.20M
|
9.80M
|
23.20M
|
3
|
— | — | — | — | — | — | — | — |
Key facts
CIK
1719406
CUSIP
629444209
13F (30d)
53 filings
49 filers
Visit website
Investor relations